CB5046

**CB5046** is a preclinical mitochondrial-derived peptide analog program from **CohBar** designed to inhibit **C-X-C chemokine receptor type 4** and thereby interfere with a pathway implicated in tumor growth, metastasis, and tumor microenvironment signaling. Reported as a potent, selective **CXCR4 receptor inhibitor** with **low-nanomolar to nanomolar binding affinity**, the program has been positioned primarily for **oncology**, including melanoma and other CXCR4-expressing cancers, with preclinical data showing enhanced antitumor activity when combined with chemotherapy such as temozolomide. CohBar has also described potential utility in **stem cell mobilization** and certain **genetic or orphan diseases** linked to CXCR4 biology. No approved product name, clinical dosage form, or marketed formulation has been publicly established.

Other names

CB5046 analogsCB-5046 analogsCB 5046 analogs